Using the small molecule inhibitor MA9, we demonstrate that ULK3 activity can be effectively blocked at nanomolar concentrations, leading to a reduction in MM tumor burden, preservation of bone integrity, and improved overall survival in vivo. This evidence concerns the gene ULK3 and Miyoshi myopathy.